Alnylam delivered its first quarter above $1.0 billion in net product revenues, posting $1,172.1 million for the three months ended June 30, 2026 (a 74 percent increase over the same period in 2025), with the second consecutive billion-dollar print following Q1 2026. The quarter was both a commercial milestone and a guidance reset. Management on July 30, 2026 lowered full-year 2026 Total TTR net product revenue guidance to $4,200 to $4,500 million from the prior $4,400 to $4,700 million, attributing the cut to a faster-than-expected normalization of second-line demand for AMVUTTRA in transthyretin amyloid cardiomyopathy (ATTR-CM) after pent-up patient demand from the post-launch window was satisfied. Alnylam also crossed into GAAP profitability for the period, reporting net income of $164.5 million ($1.23 per basic share) versus a loss of $72.2 million in Q2 2025, and operating income of $231.4 million versus a loss of $16.2 million in the prior-year quarter.
The thesis on Alnylam is that the company is no longer a pre-profit RNA interference story; it is a single-product commercial engine with a deeper pipeline that the market is increasingly pricing on AMVUTTRA's penetration curve in ATTR-CM. The bear case in late July 2026 was that the Q2 TTR revenue print of $1,030 million ($1,012 million AMVUTTRA plus $18 million ONPATTRO) signaled a launch ceiling; the bull case is that AMVUTTRA's U.S. franchise grew 124 percent year-over-year to $809 million and that Total Rare (GIVLAARI and OXLUMO) grew 11 percent to $142 million, demonstrating durable demand outside the TTR franchise. The single load-bearing risk is execution on the second-line ATTR-CM market: management's own guidance cut indicates that the early-launch pace overstated the steady-state growth rate. The falsifiable clock is the Q3 2026 print (expected late October 2026), which tests whether the new $4,200 to $4,500 million TTR band is achievable and whether the second-line normalization has fully played through.